Sign in
Not yet taking people in United StatesPhase 4

Exercise and Diet Counseling to Protect Muscle in Adults With Obesity Taking Semaglutide

Tests exercise and diet counseling to limit muscle and bone loss in adults taking semaglutide.

Key facts

Who runs it
William Marsh Rice University
Where
Houston, United StatesSee the site
Trial code
Registry title
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
Status
Not yet recruiting
Phase
Phase 4
People taking part
20 people, planned
Started
6 Apr 2026
Planned end
6 Aug 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Semaglutide
  • Dietary Counseling
  • Exercise
Record updated
28 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 to 55 with obesity who can start GLP-1 treatment. It tests whether exercise and diet counseling help keep muscle and bone.

Age
40 to 55 years
Sex
All sexes can join.
Disease stage
Obesity: BMI greater than 30, body fat greater than 30% for males and 40% for females, android to gynoid fat ratio greater than 1.0.
Earlier treatment
Currently able to have GLP-1 therapy.

Main reasons for not taking part

  • Type II diabetes
  • Abnormal ECG findings, such as arrhythmias or ischemic changes
  • Abnormal blood pressure response to exercise
  • VO₂ max below 15 ml/kg/min
  • Any reason not to exercise under ACSM guidelines, or bone and muscle problems that stop safe exercise

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age between 40 and 55 years
  • Body Mass Index (BMI) greater than 30
  • Body fat percentage greater than 30% for males and 40% for females
  • Android to gynoid fat ratio greater than 1.0
  • Currently eligible for GLP-1 therapy
  • No diagnosis of Type II diabetes

Who cannot take part

  • Presence of abnormal ECG findings, including arrhythmias or ischemic changes
  • Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg
  • Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload
  • VO₂ max below 15 ml/kg/min
  • Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads
  • Any contraindications to exercise as defined by ACSM guidelines
  • Musculoskeletal limitations that prevent safe participation in exercise

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 55 years old?

Where in United States

  • Rice UniversityHouston, United StatesContact: Anatolia Vick-KregelNot yet recruiting

About the trial

What the trial wants to find out

Obesity remains a critical public health challenge and is associated with increased rates of morbidity, mortality, and chronic disease worldwide. In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have emerged as highly effective pharmacological treatments for obesity, producing substantial weight loss and favorable metabolic improvements. These medications are now widely prescribed, with estimates suggesting that nearly 12% of Americans are currently using or have previously used GLP-1 therapies. Despite their demonstrated benefits, growing evidence indicates that GLP-1-associated weight loss may be accompanied by unintended reductions in skeletal muscle and bone mass. This potential side effect is of increasing concern, as muscle and bone are essential for metabolic health, physical function, injury prevention, and recovery from illness or surgical intervention.

Read full original descriptionShow less

Loss of skeletal muscle during weight reduction may negatively impact strength, mobility, insulin sensitivity, and long-term health outcomes. These risks may be further compounded in individuals experiencing reduced physical activity, mechanical unloading, or prolonged caloric deficits. In clinical and surgical populations, such as individuals undergoing orthopedic procedures, mechanical unloading and disuse already predispose patients to muscle and bone atrophy. When combined with pharmacologically induced weight loss, these factors may further hinder recovery, impair functional capacity, and compromise musculoskeletal integrity. As GLP-1 therapies are increasingly adopted across diverse populations, understanding how to preserve lean mass and bone health during treatment has become an important clinical and public health priority.

Exercise training, particularly resistance training, combined with appropriate nutritional support, has consistently been shown to preserve and enhance skeletal muscle and bone mass during weight loss. Structured exercise interventions can mitigate sarcopenia and osteopenia while improving muscular strength, cardiorespiratory fitness, metabolic health, and overall physical function. Similarly, individualized dietary counseling, particularly when focused on adequate protein intake and nutrient timing, plays a critical role in supporting muscle protein synthesis and skeletal health during caloric restriction. Together, these lifestyle strategies may not only counteract the potential adverse musculoskeletal effects associated with GLP-1 therapy but also enhance treatment efficacy by improving cardiovascular risk profiles, insulin sensitivity, systemic inflammation, and physical resilience.

Despite the growing use of GLP-1 medications, there remains a limited body of prospective research examining structured lifestyle interventions specifically designed to preserve muscle and bone mass during GLP-1-induced weight loss. Addressing this gap is essential to ensure that pharmacological obesity treatments support long-term health, functional independence, and quality of life. Integrating exercise and nutrition interventions into GLP-1 treatment protocols may represent a scalable and clinically meaningful strategy to optimize outcomes and reduce unintended consequences of rapid weight loss.

The purpose of this study is to evaluate whether a structured lifestyle intervention combining exercise and individualized nutritional counseling can mitigate skeletal muscle mass loss in obese adults undergoing treatment with GLP-1 receptor agonists. The primary objective of this study is to determine whether participation in a structured 12-week exercise program, in conjunction with individualized dietary counseling, preserves skeletal muscle mass and bone mineral density during GLP-1 therapy. Secondary objectives include assessing changes in muscular strength, cardiorespiratory fitness, and overall functional capacity. Findings from this study aim to inform best practices for integrating lifestyle interventions with pharmacological obesity treatments and to support safer, more effective, and functionally protective approaches to weight management in adults receiving GLP-1 therapy.

The 2 groups in the trial

  • Control Arm: GLP-1 Therapy AloneExisting treatment, for comparison

    Participants receive standard-of-care GLP-1 receptor agonist therapy (semaglutide) without additional exercise or dietary counseling.

    Treatment: Semaglutide

  • Treatment Arm: GLP-1 Therapy + Exercise and Dietary CounselingTreatment being tested

    Participants receive standard-of-care GLP-1 receptor agonist therapy (semaglutide) in combination with a 12-week structured exercise program and weekly individualized dietary counseling.

    Treatment: Dietary Counseling and Exercise

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment
Plain-language title
Exercise and Diet Counseling to Protect Muscle in Adults With Obesity Taking SemaglutideGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07554417, who can take part
Record updated
28 April 2026